Novozymes A/s

Novo Nordisk A/s

Qiagen Gmbh

Aarhus Universitet

Exiqon A/s

Region Midtjylland

Other

Novo Nordisk Healthcare Ag

Lars Kongsbak

Niels Erik Krebs Lange

Kirk Matthew Schnorr

Mads Eskelund Bj&oslash;rnvad

Lene Nonboe Andersen

Markus Sakari Kauppinen

Martin Sch&uuml;lein

Peter Mouritzen

S&oslash;ren M&oslash;ller

Martin Schulein

Sakari Kauppinen

Lars Christian Petersen

Ole Thastrup

Steffen Ernst

Henri Chanzy

Sanne O Schroder Glad

William Helbert

Søren Morgenthaler Echwald

Hanne Dela, Legal Representative

Peter Stein Nielsen

Sanne O Schr&oslash;der Glad

Karina Dalsgaard Sørensen

Tommy Lykke Husum

Torben Ørntoft

Anni Rønfeldt Thomsen

Don Foster

Niels Bergenhem

Philip Anwar Husain

Nana Jacobsen

Mikkel Nørholm

Martin Sh&uuml;lein

Torben Orntoft

Ronfeldt Anni Thomsen

Dalsgaard Karina Sorensen

Mads Eskelund Bjornvad

Søren Møller

Jens Toenne Andersen

Mads Eskelund Bjørnvad

Soren Moller

Agneta Siegbahn

Mirella Ezban

Sanne O Schrøder Glad

Helle Kristensen

Jacob Christian Fredsøe

Don Zymogenetics Foster

RØNFELDT Anni Thomsen

Dalsgaard Karina SØRENSEN

Jacob Christian FREDSØE

Mikkel Norholm

Jacob Christian Fredsoe

Soren Morgenthaler Echwald

The present application concerns a new in vitro method for assessing the risk that a subject suffers from prostate cancer. The method comprises measuring the expression level the level of at least two miRs selected from group of miRs consisting of: hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7e-5p, hsa-let-7f-5p, hsa-let-7g-5p, hsa-miR-100-5p, hsa-miR-106a-5p, hsa-miR-10a-5p, hsa-miR-10b-5p, hsa-miR-1238-3p, hsa-miR-125b-5p, hsa-miR-1260a, hsa-miR-130a-3p, hsa-miR-132-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, hsa-miR-136-5p, hsa-miR-140-3p, hsa-miR-141-3p, hsa-miR-142-3p, hsa-miR-146a-5p, hsa-miR-148a-3p, hsa-miR-151a-3p, hsa-miR-151a-5p, hsa-miR-15b-5p, hsa-miR-16-5p, hsa-miR-191-5p, hsa-miR-1972, hsa-miR-19a-3p, hsa-miR-19b-3p, hsa-miR-200a-3p, hsa-miR-200b-3p, hsa-miR-200b-5p, hsa-miR-200c-3p, hsa-miR-203a, hsa-miR-204-5p, hsa-miR-205-5p, hsa-miR-20a-5p, hsa-miR-210, hsa-miR-222-3p, hsa-miR-223-3p, hsa-miR-22-5p, hsa-miR-23a-3p, hsa-miR-23b-3p, hsa-miR-24-3p, hsa-miR-25-3p, hsa-miR-26a-5p, hsa-miR-27b-3p, hsa-miR-29a-3p, hsa-miR-29b-3p, hsa-miR-29c-3p, hsa-miR-30a-3p, hsa-miR-30a-5p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-30e-5p, hsa-miR-31-3p, hsa-miR-31-5p, hsa-miR-320a, hsa-miR-320b, hsa-miR-320c, hsa-miR-331-3p, hsa-miR-362-3p, hsa-miR-362-5p, hsa-miR-363-3p, hsa-miR-375, hsa-miR-378a-3p, hsa-miR-425-3p, hsa-miR-425-5p, hsa-miR-455-3p, hsa-miR-490-3p, hsa-miR-660-5p, hsa-miR-93-5p, hsa-miR-99a-5p, and hsa-miR-99b-5p, in a urine sample from the patient. A method wherein the at least two selected miRs are: hsa-miR-30c-5p, hsa-miR-222-3p, and hsa-miR-24-3p is preferred. The application also concerns a kit of parts to perform the in vitro method.

MicroRNA-based method for early detection of prostate cancer in urine samples

The present application concerns a new in vitro method for assessing the prognosis of a prostate cancer patient, comprising measuring the expression level of at least two miRs selected from group of miRs consisting of: miR-106a-5p, miR-10b-5p, miR-133a-3p, mi R-152-3p, miR-185-5p, miR-193a-5p, miR-221-3p, miR-23a-3p, miR-30d-3p, miR-326, mi R-374b-5p, miR-615-3p and mi R-625-3p in a RNA sample from prostate cells obtained from said patient, wherein a changed expression level of said at least 2 miRs, as compared to a reference expression profile, is indicative of the prognosis of said prostate cancer patient.

Microrna-based method for assessing the prognosis of a prostate cancer patient

The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.

Methods for quantification of microRNAs and small interfering RNAs

The present invention relates to pectate lyases comprising the amino acid sequence Asn Leu Asn Ser Arg Val Pro (NLNSRVP) (amino acids 236-242 of SEQ ID NO: 2) belonging to Family 1 of polysaccharide lyases have good performance in industrial processes under neutral or alkaline conditions such as laundering and textile processing. The pectate lyase may be derivable fromspecies.

Pectate lyases

The present invention relates to pectate lyases comprising the amino acid sequence Asn Leu Asn Ser Arg Val Pro (NLNSRVP) (amino acids 236&#x2013;242 of SEQ ID NO: 2) belonging to Familyof polysaccharide lyases have good performance in industrial processes under neutral or alkaline conditions such as laundering and textile processing. The pectate lyase may be derivable fromspecies.

The present invention relates to pectate lyases comprising the amino acid sequence Asn Leu Asn Ser Arg Val Pro (NLNSRVP) (SEQ ID NO: 2) belonging to Family 1 of polysaccharide lyases have good performance in industrial processes under neutral or alkaline conditions such as laundering and textile processing. The pectate lyase may be derivable from Bacillus species.

The present invention provides methods for high-temperature biopreparation of cellulosic fibers by contacting the fibers with pectin-degrading enzymes, preferably thermostable, alkaline, divalent cation-independent pectate lyases, under conditions compatible with scouring and bleaching technologies.

Biopreparation of textiles at high temperatures

The invention relates to a ellulose film comprising microfibrillated cellulose and to the use of it for screening of a biological compound and nucleic acids encoding a biological compound.

Cellulose films for screening

The present invention provides methods for modifying the motility of tissue factor (TF)-expressing cells, which are carried out by contacting such cells with an effective amount of Factor VIIai Factor VIIa agonist.

Methods for modifying cell motility using factor VIIa or inactivated factor VIIa

The invention relates to a cellulose film comprising microfibrillated cellulose and to the use of it for screening of a biological compound and nucleic acids encoding a biological compound.

A novel pectate lyase belonging to a novel family of polysaccharide lyases has good performance in industrial processes under neutral or alkaline conditions such as laundering and textile processing. The pectate lyase may be derivable from Bacillus species.

A novel group of pectate lyases comprising the amino acid sequence Asn Leu Asn Ser Arg Val Pro (NLNSRVP) belonging to Family 1 of polysaccharide lyases have good performance in industrial processes under neutral or alkaline conditions such as laundering and textile processing. The pectate lyase may be derivable from Bacillus species.

The present invention provides methods for identifying candidate drugs that modulate factor VIIa-mediated intracellular signaling by measuring the effects of such drugs on the activation of the mitogen-activated protein kinase (MAP kinase) signaling pathway.

Identification of drug candidates modulating factor VII-mediated intracellular signaling

The present invention provides methods for higha-temperature biopreparation of cellulosic fibers by contacting the fibers with pectin-degrading enzymes, preferably thermostable, alkaline, divalent cation-independent pectate lyases, under conditions compatible with scouring and bleaching technologies.

Growing community of inventors

Holte, Denmark

Lars Kongsbak